Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Myricx Bio | 2024 | Series A | $115.3M | London |
| Bluejay Therapeutics | 2024 | Series C | $182.0M | San Mateo |
| Clasp Therapeutics | 2024 | Series A | $150.0M | Cambridge |
| Asgard Therapeutics | 2024 | Series A | $32.6M | Lund |
| Revagenix | 2024 | Series B | Undisclosed | San Mateo |
| Hoba Therapeutics | 2023 | Series A | $24.8M | Copenhagen |
| Doctor Anywhere | 2023 | Series C | $40.8M | Singapore |
| Exscientia | 2023 | Grant | $2.3M | Oxford |
| Arcellx | 2023 | Post Ipo Equity | $200.0M | Redwood City |
| Terremoto Biosciences | 2023 | Series B | $175.0M | San Francisco |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 101 | Myricx Bio | Series A | $115.3M | London, United Kingdom |
| 102 | Bluejay Therapeutics | Series C | $182.0M | San Mateo, United States |
| 103 | Clasp Therapeutics | Series A | $150.0M | Cambridge, United States |
| 104 | Asgard Therapeutics | Series A | $32.6M | Lund, Sweden |
| 105 | Revagenix | Series B | Undisclosed | San Mateo, United States |
| 106 | Hoba Therapeutics | Series A | $24.8M | Copenhagen, Denmark |
| 107 | Doctor Anywhere | Series C | $40.8M | Singapore, Singapore |
| 108 | Exscientia | Grant | $2.3M | Oxford, United Kingdom |
| 109 | Arcellx | Post Ipo Equity | $200.0M | Redwood City, United States |
| 110 | Terremoto Biosciences | Series B | $175.0M | San Francisco, United States |
Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.
Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.
Clasp Therapeutics offers to reach of immuno-oncology with novel precision medicines that enable the immune system.
Asgard Therapeutics is a Biotechnology Company.
Revagenix is a biopharmaceutical company discovering and developing therapies to address medical needs.
Hoba Therapeutics is developing a new therapeutic protein for the treatment of neuropathic pain.
Doctor Anywhere is a telehealth company .
Exscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new drugs.
Arcellx develops engineered cell-based immunotherapies for the treatment of cancer and other serious diseases.
Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines.
Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.
Acesion Pharma is a developer of medical drugs designed for the treatment of atrial fibrillation.
Halodoc is a health-tech platform that connects patients with doctors, insurance, labs, and pharmacies.
Inozyme is a biopharmaceutical company developing therapeutics for rare diseases, with a focus on bone health.
CorWave is a medical device company developing innovative heart pumps.
Roslin Technologies is a biotechnology company that focuses on developing technologies for the agricultural and animal health sectors.
Morphic Therapeutic is a biotechnology company that develops oral integrin therapies to treat serious chronic diseases.
Aquafortus is a non-thermal recovery and crystallization technology platform.
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.
Breye Therapeutics, a biopharmaceutical firm that provide cutting-edge oral treatments for the management of retinal vascular diseases.
Kate Farms offers plant-based shakes and formulas for tube-fed adults and children.
Zhenge Biotech is a macromolecular pharmaceutical contract development and manufacturing organisation.
Inspirna is a biotechnology company developing drugs for the treatment of cancer.
Invetx is a veterinary therapeutics company that develops protein-based therapeutics for the treatment of various animal diseases.
Engimmune Therapeutics is a platform and product development company engineering next-generation T cell receptor therapies.
Novo Holdings has invested in 154 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Novo Holdings's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Medical, Therapeutics. The firm invests across 29 different industry categories.
Among tracked funding rounds, Morphic Therapeutic received $276.0M in a Post Ipo Equity round. Novo Holdings's total known invested capital is $8.5B.
Novo Holdings's average investment size is $69.9M across its portfolio of 154 companies.
Recent Novo Holdings portfolio additions include Myricx Bio, Bluejay Therapeutics, Clasp Therapeutics, Asgard Therapeutics, Revagenix. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors